PROTEINA

🎉 Collaboration with JW Pharmaceutical! 🎉 We are thrilled to announce that we have entered into a collaboration partnership with JW Pharmaceutical to develop innovative biomarkers for their first-in-class STAT3 inhibitor drug candidate, soon to enter clinical trials. JW-2286 is a new first-in-class drug candidate with a novel mechanism of action that inhibits STAT3 and indicated for the treatment of solid tumors, incl. triple-negative breast cancer, gastric cancer, and colorectal cancer. We will be leveraging our proprietary SPID Platform to overcome limitations associated with traditional methods like IHC staining in analyzing STAT3 expression. We are thrilled to call another major drug developer our partner and we are confident that the partnership will reach its desired outcome! 👏 A huge shout out to the tireless efforts from our PROTEINA team and many thanks to JW Pharmaceutical for supporting our technology! #PROTEINA #BiomarkerInnovation #STAT3 #PrecisionMedicine #CancerTherapy #ClinicalTrials #BiotechPartnerships https://lnkd.in/gi9-feja

Day 3 of the PEGS Europe is complete! I was a bit nervous, but presenting the talk gave me a fantastic opportunity to connect and communicate, exchanging the ideas and sharing insights about our platform's potential impact on antibody engineering. Team PROTEINA had the pleasure of meeting over 100 scientists, learning from each interaction. We look forward to reconnecting and engaging at future events!

Day 1 at PEGS Europe 2024 flew by! Team PROTEINA had a fantastic time introducing our SPID technology and PPI Landscape to leading scientists at booth #207 and during our poster presentation. We’re excited for another day of networking and discussing advancements in antibody engineering. If you're at the conference, stop by booth #207—we’d love to connect!

Another productive day at PEGS Europe 2024 has wrapped up! 🌍 Today is the last chance to visit us at Booth #207 and explore the future of antibody engineering and optimization. I'll be presenting on SPID’s role in advancing bispecific antibody development, focusing on high-throughput, purification-free assessment of heavy and light chain assembly. Looking forward to insightful discussions—let’s connect! #PEGS2024 #AntibodyEngineering #SPIDPlatform #BispecificAntibodies PROTEINA

📣 Presentation at PEGS Europe 2024 Join us at PEGS Europe for two presentations showcasing the latest advancements in our PPI Landscape solution. See how our antibody optimization solution can support your projects and drive success in drug development. 🔸Podium Presentation: Speaker: Jihye Jo, Ph.D. (Principal Scientist) Title: High-Throughput Bispecific Antibody Optimization via Purification-Free Single-Molecule Fluorescence Imaging 🔸Poster Presentation: Presenter: BooYoung Yu, M.S. (Researcher) Title: Advancing Antibody Engineering and Maturation with High-Throughput Single-Molecule Imaging System #PEGSEurope #PROTEINA #biotechnology #antibodies #optimization

📢 PROTEINA at PEGS Europe 2024 We are excited to announce that PROTEINA will be sponsoring PEGS Europe 2024 in Barcelona, Spain, from November 5th to 7th! We'll be showcasing our comprehensive antibody optimization solution, PPI Landscape, and we’d love for you to stop by our booth. Find us at booth 207! Our team of experts will be happy to answer any questions and discuss antibody optimization with you. We hope to connect with you there! #PEGSEurope #PROTEINA #biotechnology #antibodies #optimization

🚀 MOU Signing with Daan Biotherapeutics 🚀 We are excited to announce a new R&D partnership aimed at advancing the development and optimization of TCR therapies currently being developed by Daan Biotherapeutics, an innovative biotech company focusing on cancer therapies. 🎯💊 With this MOU, we are expediting the commercialization of our PPI Landscape Solution 🔬, powered by our SPID (Single molecule Protein Interaction Detection) platform. This solution enables ultra-fast, high-resolution analysis of PPI (protein-protein interaction), including antibody-antigen binding, using minimal sample quantities and no need for purification. 🧬We expect superior outcomes vs existing technology to help our partners accelerate antibody discovery, affinity maturation, and therapeutic development! 💡 This partnership with Daan Biotherapeutics, led by the renowned Cho Byoung Chul (CEO) 👨⚕️, who played a pivotal role in the clinical success of the anticancer drug Leclaza (lazertinib), further enhances our shared mission to revolutionize the future of cancer therapies and precision medicine. 🌟 #BiotechInnovation 🔬 #CancerTherapies 💊 #SPID ⚙️ #ProteinInteraction 🧬 #TCRTherapy 🧪 #AntibodyDiscovery 🧫 #PPIPlatform ⚛️ #TherapeuticDevelopment 💡 #PROTEINA 🌍 #DaanBiotherapeutics 🤝 #Collaboration 🤝 #PPILandscape

🧬 PROTEINA will be attending ChinaBio Partnering Forum 2024 We are pleased to announce that PROTEINA will be participating in the ChinaBio Partnering Forum from September 10th and 11th at The Kerry Hotel Pudong in Shanghai 🔍 Arrange a Meeting with Us! We're excited to discuss how our innovative solutions can benefit your projects and contribute to your success in proteomic research and drug development. #ChinaBio #PROTEINA #biotechnology #proteomics #precisionmedicine #PPI

🌟 Stories @ PROTEINA 🙌 Meet our Chief Research Officer, Byoungsan Choi! A passionate architect of PROTEINA's future, Byungsan is leading the charge in research and development. He's empowering our team to think big, dream boldly, and create groundbreaking solutions. #EmployeeSpotlight #PROTEINA

🎉 Happy 9th Birthday, PROTEINA! 🎉 From humble beginnings in the halls of academia starting on August 5, 2015, to where we stand today, the last 9 years has been an incredible journey. The path less travelled has been bumpy and difficult at times, but resilience and perseverance has guided us throughout. Over the past 12 months, we've made significant strides with our platform and global partners, and we couldn't have done it without the support and at times constructive criticism from partners, colleagues, and shareholders. Hats off to many more milestones and celebrations in the years to come! 🚀 Year 9 Milestones 🚀 🔹 People: Our PROTEINA family has grown from 1 to 52. 🔹 Funding: Raised over $30M in 4 rounds, even during tough times. 🔹 Clients: From only a belief in our technology to 4 global pharma clients and more on the horizon. 🔹 Expansion: Opened a state-of-the-art manufacturing facility and moved to new offices. (We'll always cherish the beautiful SNU campus scenery). 🌟 Our 3 Birthday Wishes! 🌟 🔹Fruition of our PPI Landscape business and AI Antibody Discovery Project. 🔹Expansion of our PPI pathfinder business in clinical trials/Dx. 🔹Listing on the stock exchange to further expedite our growth. Thank you for being a part of our journey! 💪 #Anniversary #Biotech #Innovation #Growth #PROTEINA #PPI #AIDrugDiscovery